Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma

Clinical Reviews in Allergy and Immunology

Volumn 43, Issue 3, 2012, Pages 249-255

  Moinzadeh, Pia ^a   Nihtyanova, Svetlana I ^a   Howell, Kevin ^a   Ong, Voon H ^a   Denton, Christopher P ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antinuclear antibody; Raynaud; Scleroderma; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; RNA ANTIBODY;

ARTICLE; CAPILLAROSCOPY; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; EARLY DIAGNOSIS; PREDICTIVE VALUE; RAYNAUD PHENOMENON; SEROLOGY; SURVIVAL; SYSTEMIC SCLEROSIS;

ANTIBODIES, ANTINUCLEAR; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; RAYNAUD DISEASE; SCLERODERMA, LOCALIZED;

EID: 84871666435     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-012-8331-1     Document Type: Article

References (49)

1. Fransen J, Johnson SR, van den Hoogen F et al (2012) Items for developing revised classification criteria in systemic sclerosis: results of a consensus exercise. Arthritis Care Res (Hoboken) 64:351-357
2. Johnson SR, Fransen J, Khanna D et al (2012) Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 64(3):358-367
3. Avouac J, Fransen J, Walker UA et al (2011) Preliminary criteria for the very early diagnosis of systemic sclerosis (VEDOSS): results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 70(3):476-481
4. Raynaud M 1888: Local Asphyxia and Symmetrical Gangrene of the Extremities 1862. New Researches on the Nature and Treatment of Local Asphyxia of the Extremities 1874. Translated by Barlow T. London: New Sydenham Society
5. Wigley FM (2002) Clinical practice. Raynaud's phenomenon. N Engl J Med 347(13):1001-1008
6. Goundry B, Bell L, Langtree M, Moorthy A (2012) Diagnosis and management of Raynaud's phenomenon. BMJ 344:e289
7. Jones GT, Herrick AL, Woodham SE, Baildam EM, Macfarlane GJ, Silman AJ (2003) Occurrence of Raynaud's phenomenon in children ages 12-15 years: prevalence and association with other common symptoms. Arthritis Rheum 48(12):3518-3521 (Pubitemid 37531918)
8. Suter LG, Murabito JM, Felson DT, Fraenkel L (2005) The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 52(4):1259-1263 (Pubitemid 40530134)
9. Freedman RR, Mayes MD (1996) Familial aggregation of primary Raynaud's disease. Arthritis Rheum 39(7):1189-1191 (Pubitemid 26240233)
10. Denton CP, Black CM (2004) Scleroderma -clinical and pathological advances. Best Pract Res Clin Rheumatol 18(3):271-290
11. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28(7):1573-1576 (Pubitemid 32660630)
12. Matucci-Cerinic M, Allanore Y, Czirják L et al (2009) The challenge of early systemic sclerosis for the EULAR Scleroderma trial and research group (EUSTAR) community. It is time to cut theGordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 68(9):1377-1380
13. Herrick AL (2005) Pathogenesis of Raynaud's phenomenon. Rheumatol (Oxford) 44(5):587-596 (Pubitemid 41487226)
14. Herrick AL (2011) Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Curr Opin Rheumatol 23(6):555-561
15. Galluccio F, Matucci-Cerinic M (2011) Two faces of the same coin: raynaud phenomenon and digital ulcers in systemic sclerosis. Autoimmun Rev 10(5):241-243
16. Sunderkötter C, Riemekasten G (2006) Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Rheumatol (Oxford) 45:iii33-iii35 (Pubitemid 44446775)
17. Nihtyanova SI, Tang EC, Coghlan JG, Wells AU, Black CM, Denton CP (2010) Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 103(2):109-115
18. Domsic RT, Medsger TA (2012) Disease subsets in clinical practice. In: Varga J, Denton CP, Wigley FM (eds) Scleroderma. From pathogenesis to comprehensive treatment. Springer, New York, pp 45-52
19. Masi AT, Rodnan GP, Medsger TA Jr et al (1980) Subcommittee for scleroderma criteria of american rheumatism association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590
20. Maricq HR, LeRoy EC (1973) Patterns of finger capillary abnormalities in connective tissue disease by "wide-field" microscopy. Arthritis Rheum 16(5):619-628
21. Moore TL, Roberts C, Murray AK, Helbling I, Herrick AL (2010) Reliability of dermoscopy in the assessment of patients with Raynaud's phenomenon. Rheumatol (Oxford) 49(3):542-547
22. Anders HJ, Sigl T, Schattenkirchner M (2001) Differentiation between primary and secondary Raynaud's phenomenon: a prospective study comparing nailfold capillaroscopy using an ophthalmoscope or stereomicroscope. Ann Rheum Dis 60(4):407-409 (Pubitemid 32242757)
23. Cutolo M, Grassi W, Matucci Cerinic M (2003) Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 48 (11):3023-3030, Review (Pubitemid 37409311)
24. Hoerth C, Kundi M, Katzenschlager R, Hirschl M (2012) Qualitative and quantitative assessment of nailfold capillaries by capillaroscopy in healthy volunteers. Vasa 41(1):19-26
25. Bukhari M, Hollis S, Moore T, Jayson MI, Herrick AL (2000) Quantitation of microcirculatory abnormalities in patients with primary Raynaud's phenomenon and systemic sclerosis by video capillaroscopy. Rheumatol (Oxford) 39(5):506-512 (Pubitemid 30352954)
26. Nagy Z, Czirják L (2004) Nailfold digital capillaroscopy in 447 patients with connective tissue disease and Raynaud's disease. J Eur Acad Dermatol Venereol 18(1):62-68 (Pubitemid 38165264)
27. Cutolo M, Pizzorni C, Tuccio M et al (2004) Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatol (Oxford) 43(6):719-726 (Pubitemid 38807428)
28. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr (2007) Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 34(1):104-109 (Pubitemid 46106569)
29. Graf SW, Hakendorf P, Lester S et al (2012) South Australian scleroderma register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 15(1):102-109
30. Mierau R, Moinzadeh P, Riemekasten G et al (2011) Frequency of disease-Associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 13(5):R172
31. Hénault J, Tremblay M, Clément I, Raymond Y, Senécal JL (2004) Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 50:3265-3274
32. Villalta D, Tozzoli R, Tonutti E, Bizzaro N (2007) The laboratory approach to the diagnosis of autoimmune diseases: is it time to change? Autoimmun Rev 6(6):359-365 (Pubitemid 46830688)
33. Reveille JD, Solomon DH, American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines (2003) Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 49 (3):399-412 (Pubitemid 36682409)
34. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr (2003) A comparison between anti-Th/To-And anticentromere antibodypositive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 48(1):203-209 (Pubitemid 36091664)
35. Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr (2009) Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 60(4):1112-1118
36. Fertig N, Domsic RT, Rodriguez-Reyna T et al (2009) Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 61(7):958-965
37. Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr (2005) Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 52(8):2425-2432 (Pubitemid 41117428)
38. Basu D, Reveille JD (2005) Anti-scl-70. Autoimmunity 38(1):65-72 (Pubitemid 40515005)
39. Walker UA, Tyndall A, Czirják L et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 66(6):754-763 (Pubitemid 46846694)
40. Nihtyanova SI, Denton CP (2010) Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 6(2):112-116
41. Steen vD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66:940-944 (Pubitemid 46999798)
42. Mahler M, Raijmakers R (2007) Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 6(7):432-437 (Pubitemid 47069969)
43. Penn H, Howie AJ, Kingdon EJ et al (2007) Scleroderma renal crisis: patient characteristics and long-Term outcomes. QJM 100 (8):485-494 (Pubitemid 47241915)
44. Ziegler S, Brunner M, Eigenbauer E, Minar E (2003) Long-Term outcome of primary Raynaud's phenomenon and its conversion to connective tissue disease: a 12-year retrospective patient analysis. Scand J Rheumatol 32(6):343-347 (Pubitemid 38177790)
45. Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M (2006) Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 54(6):1974-1981 (Pubitemid 43877947)
46. Koenig M, Joyal F, Fritzler MJ et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58 (12):3902-3912
47. Ingegnoli F, Boracchi P, Gualtierotti R et al (2010) Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy. Rheumatol (Oxford) 49(4):797-805
48. Spencer-Green G (1998) Outcomes in primary Raynaud phenomenon: a meta-Analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 158(6):595-600 (Pubitemid 28144816)
49. Cutolo M, Pizzorni C, Sulli A (2007) Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al. Arthritis Rheum 56(6):2102-2103 (Pubitemid 47110417)